Regulation of tissue factor expression in human microvascular endothelial cells by nitric oxide.

BACKGROUND Tissue factor (TF) is a critical determinant of thrombin generation in normal hemostasis and in atherothrombotic disease. Nitric oxide has both antithrombotic and antiatherosclerotic actions in the vasculature, yet its role in the regulation of TF expression has not been examined. METHODS AND RESULTS To study the effect of endogenous endothelium-derived nitric oxide on TF expression and activity, we induced TF in human microvascular endothelial cells with lipopolysaccharide or interleukin-1beta and observed a dose- and time-dependent increase in TF activity and expression by Northern and Western blotting. L-Arginine, the principal substrate for nitric oxide synthases, added to the media suppressed the induction of TF activity significantly (by 66% for lipopolysaccharide induction and by 59% for interleukin-1beta induction) at 24 hours. These changes in activity were accompanied by correlative changes in TF protein and steady-state mRNA. D-Arginine had no effect, and inhibition of endogenous nitric oxide production failed to increase TF expression. CONCLUSIONS These data suggest that enhanced production of endothelium-derived nitric oxide reduces endotoxin- and cytokine-induced expression of TF and, thereby, the prothrombotic phenotype of the endothelial cell.

[1]  G. Welch,et al.  Nitric Oxide and the Cardiovascular System , 2000, Contemporary Cardiology.

[2]  J. Loscalzo,et al.  Nitric Oxide Inhibits Thrombin Receptor-activating Peptide-induced Phosphoinositide 3-Kinase Activity in Human Platelets* , 1999, The Journal of Biological Chemistry.

[3]  J. Loscalzo,et al.  Impaired platelet production of nitric oxide predicts presence of acute coronary syndromes. , 1998, Circulation.

[4]  W. Sessa,et al.  Hypotension and inflammatory cytokine gene expression triggered by factor Xa-nitric oxide signaling. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[5]  P. Carmeliet,et al.  Low levels of tissue factor are compatible with development and hemostasis in mice. , 1998, The Journal of clinical investigation.

[6]  B. Østerud.  Tissue Factor: a Complex Biological Role , 1997, Thrombosis and Haemostasis.

[7]  J. Fallon,et al.  Tissue Factor in the Pathogenesis of Atherosclerosis , 1997, Thrombosis and Haemostasis.

[8]  B. Osterud,et al.  Tissue Factor: a Complex Biological Role , 1997, Thrombosis and Haemostasis.

[9]  J. Fallon,et al.  In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[10]  J. Loscalzo,et al.  Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis. , 1996, The Journal of clinical investigation.

[11]  Y. Yu,et al.  Coinduction of Nitric Oxide Synthase, Argininosuccinate Synthetase, and Argininosuccinate Lyase in Lipopolysaccharide-treated Rats , 1996, The Journal of Biological Chemistry.

[12]  J. Loscalzo,et al.  Nitric oxide and its role in the cardiovascular system. , 1995, Progress in cardiovascular diseases.

[13]  S. Rapaport,et al.  The Tissue Factor Pathway: How It Has Become a “Prima Ballerina” , 1995, Thrombosis and Haemostasis.

[14]  C. Lowenstein,et al.  Induction of NO synthase in rat cardiac microvascular endothelial cells by IL-1 beta and IFN-gamma. , 1995, The American journal of physiology.

[15]  J. Loscalzo,et al.  Impaired EDRF production by endothelial cells exposed to fibrin monomer and FDP. , 1995, The American journal of physiology.

[16]  C. Lowenstein,et al.  Induction of NO synthase in rat cardiac microvascular endothelial cells by IL-1β and IFN-γ , 1995 .

[17]  S Amerini,et al.  Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. , 1994, The Journal of clinical investigation.

[18]  P. Peristeris,et al.  Evidence that nitric oxide is an endogenous antiangiogenic mediator , 1994, British journal of pharmacology.

[19]  J. Pearson,et al.  Vessel wall interactions regulating thrombosis. , 1994, British medical bulletin.

[20]  J. Stamler,et al.  Antiplatelet properties of protein S-nitrosothiols derived from nitric oxide and endothelium-derived relaxing factor. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[21]  H. Anderson,et al.  Endogenous Nitric Oxide Protects Against Platelet Aggregation and Cyclic Flow Variations in Stenosed and Endothelium‐Injured Arteries , 1992, Circulation.

[22]  S. Abramson,et al.  Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase. , 1992, The Journal of clinical investigation.

[23]  E. Jaffe,et al.  Cytokine-activated endothelial cells express an isotype of nitric oxide synthase which is tetrahydrobiopterin-dependent, calmodulin-independent and inhibited by arginine analogs with a rank-order of potency characteristic of activated macrophages. , 1991, Biochemical and biophysical research communications.

[24]  N. Mackman,et al.  The Structural Biology of Expression and Function of Tissue Factor , 1991, Thrombosis and Haemostasis.

[25]  R. Palmer,et al.  Nitric oxide and prostacyclin. Divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[26]  S. Moncada,et al.  Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Loscalzo,et al.  Inhibition of fibrinogen binding to human platelets by S-nitroso-N-acetylcysteine. , 1990, The Journal of biological chemistry.

[28]  Kathleen M. Smith,et al.  Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Y. Nemerson.  Tissue factor and hemostasis. , 1988, Blood.

[30]  L. Ignarro,et al.  Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[31]  C. Esmon,et al.  Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. , 1987, The Journal of clinical investigation.

[32]  W. Fiers,et al.  Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[33]  D. Stern,et al.  Modulation of endothelial cell hemostatic properties by tumor necrosis factor , 1986, The Journal of experimental medicine.

[34]  W. Kisiel,et al.  Self-regulation of procoagulant events on the endothelial cell surface , 1985, The Journal of experimental medicine.

[35]  R. Cotran,et al.  Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells , 1984, The Journal of experimental medicine.

[36]  N. Semeraro,et al.  Cultured human endothelial cells generate tissue factor in response to endotoxin. , 1983, The Journal of clinical investigation.

[37]  Y. Nemerson,et al.  [5] Purification and characterization of tissue factor apoprotein , 1976 .

[38]  Y. Nemerson,et al.  Purification and characterization of tissue factor apoprotein. , 1976, Methods in enzymology.

[39]  B. Saville.  A scheme for the colorimetric determination of microgram amounts of thiols , 1958 .